Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

125.81 -0.49 (-0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 837,342
Open 124.29
Bid (Size) 124.02 (2)
Ask (Size) 126.98 (2)
Prev. Close 126.30
Today's Range 123.97 - 126.19
52wk Range 110.03 - 238.00
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above... 
Via StockStory
Topics World Trade
Exposures Tariff

Performance

YTD
-16.1%
-16.1%
1 Month
+5.8%
+5.8%
3 Month
-8.2%
-8.2%
6 Month
-20.4%
-20.4%
1 Year
-44.1%
-44.1%

More News

Read More
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For May 1, 2025
Via Benzinga
14 Analysts Have This To Say About Biogen
Via Benzinga
3 Cash-Producing Stocks Skating on Thin Ice
Via StockStory
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
Via StockStory
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
Via StockStory
4 Stocks to Buy for a Potential “Summer Panic”
Via InvestorPlace
Exposures COVID-19
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Via Benzinga
Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Biogen Earnings: What To Look For From BIIB
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
Via StockStory
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
Via Benzinga
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
From Biogen Inc.
Via GlobeNewswire
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
What 14 Analyst Ratings Have To Say About Biogen
Via Benzinga
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Via Benzinga
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Via The Motley Fool
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
From Biogen Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 125.81
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 05/23/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 18.34B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 18B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.